Healthkart’s Financials, Revenue, Profit, Valuation & Shareholding Overview (2025)
Legal Name: Bright Lifecare Private Limited | CIN: U51909DL2011PTC218346
HealthKart, founded in 2011 by Sameer Maheshwari and Prashant Tandon, is a Gurugram-based omni-channel health and nutrition retailer offering a wide array of supplements, wellness products, and personalized nutrition services. Leveraging data-driven insights, digital platforms, and a robust distribution network across online and offline channels, HealthKart achieved a major turnaround in FY24 by surpassing ₹1,000 Cr in revenue and reporting profitability, underlining its leadership in India’s nutrition market.
| Founding year | 2011 |
|---|---|
| Headquarters | Gurugram, Haryana, India |
| Valuation | ~$500M (2024) |
| Total Funding | ~$221M over 8 rounds |
| Employees | ~1,200 (2024) |
| Annual Revenue (INR) | ₹1,021 Cr (FY24) |
| Annual Net Profit/Loss (INR) | ₹37 Cr profit (FY24) |
| EBITDA Margin | ~3.5% (FY24) |
| Round | Date | Amount | Valuation | Investors |
|---|---|---|---|---|
| Seed | 2012 | Undisclosed | Not disclosed | Angel investors |
| Series A | 2015 | $7M | Not disclosed | Blume Ventures, Angel Investors |
| Series B | 2017 | $14M | Not disclosed | Temasek, A91 Partners |
| Series C | 2020 | $35M | ~$300M | Sequoia India, Temasek |
| Series D | Nov 2022 | $135M | $500M valuation | ChrysCapital, Motilal Oswal, A91 Partners |
| Secondary Round | Jun 2024 | $153M | $500M valuation | ChrysCapital, Motilal Oswal |
HealthKart’s revenue increased from ₹491 Cr in FY22 to ₹832 Cr in FY23 (↑70%) and to ₹1,021 Cr in FY24 (↑23%), while net loss of ₹309 Cr in FY22 narrowed to ₹164 Cr loss in FY23 and turned to ₹37 Cr profit in FY24, reflecting strong unit economics improvements.
EBITDA margins improved from ~-62.9% in FY22 to ~-16.6% in FY23 and to ~3.5% in FY24, driven by optimized operations, cost control, and scale benefits.
Employee count grew from ~900 in FY22 to ~1,100 in FY23 and ~1,200 in FY24, supporting expanded online-offline distribution, technology, and customer service teams.
- Expand product portfolio into personalized nutrition and wellness services through digital platform enhancements.
- Strengthen offline retail presence and omni-channel integration to boost customer reach.
- Leverage data analytics and AI for personalized recommendations, supply chain optimization, and inventory management.
- Optimize unit economics via cost controls, private labels, and operational efficiencies in distribution.
- Prepare for potential future exit or strategic partnership after sustained profitable growth.
In FY24, HealthKart reported revenue of ₹1,021 Cr (↑23% YoY) and net profit of ₹37 Cr, a sharp recovery from a ₹164 Cr loss in FY23. The company also achieved full-year EBITDA profitability. In mid-2024, HealthKart raised $153M in a secondary round led by ChrysCapital and Motilal Oswal, valuing it around $500M, and announced an ESOP buyback worth ₹55 Cr, marking strong investor confidence.
| Metric | Details |
|---|---|
| Employees | 900 → 1100 → 1200 |
| Revenue | ₹491 Cr → ₹832 Cr (↑70%) → ₹1021 Cr (↑23%) |
| Net Profit/Loss | ₹309 Cr loss → ₹164 Cr loss → ₹37 Cr profit |
| EBITDA Margin | -62.9% → -16.6% → 3.5% |
| Valuation & Funding | $500M valuation; ~$221M total funding over 8 rounds |
| IPO Status | Private; focusing on profitable growth before considering exit. |
| Expansion Focus | Product portfolio expansion, digital platform enhancements, offline retail growth, personalized nutrition services. |
| Latest News | ₹1,021 Cr revenue, ₹37 Cr profit FY24; $153M secondary round in 2024 |
HealthKart’s notable turnaround to profitability in FY24 and strong revenue growth underscore its leadership in India’s health and nutrition sector. Continued focus on omni-channel expansion, personalized offerings, and operational efficiency will be critical to sustaining growth and long-term value creation.
Make smarter business decisions with verified insights on companies and directors. Visit Affluense.ai to learn more.
Disclaimer: © 2025. All information is curated from public and third-party sources and provided solely for legitimate business use. Please ensure proper authorization before use.